Q3 2023 Results
Company overview
Financial review
Conclusions
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
LeqvioⓇ - siRNA (regulation of LDL-C)
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
NCT03705234 ORION-4 (CKJX839B12301)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Readout
Milestone(s)
Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH)
Phase 3
15000
A composite of major adverse cardiovascular events, defined as:
Coronary heart disease (CHD) death;
Myocardial infarction;
Fatal or non-fatal ischaemic stroke; or
Urgent coronary revascularization procedure
Arm 1: every 6 months treatment Inclisiran sodium 300mg (given by
subcutaneous injection on the day of randomization, at 3 months and then
every 6-months) for a planned median duration of about 5 years
Arm 2: matching placebo (given bysubcutaneous injection on the day of
randomization, at 3 months and then every 6 months) for a planned median
duration of about 5 years.
Patient population with mean baseline LDL-C ≥ 100mg/dL
2026
Publication
TBD
47 Investor Relations | Q3 2023 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation